Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2016 call → NOWe need to determine if management's forward account consists of narrating what its counterparties are themselves doing and scaling. The question asks: does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company ALREADY SUPPLIES OR SERVES, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to look at the transcript. Management discusses Term Life, ISP, recruiting, DOL rule, etc. They talk about their own sales force, recruiting, licensing, etc. They talk about the DOL rule and their preparations. They talk about their own technology platform. They talk about their own repurchases. They talk about their own product sales. They mention industry trends like MIB Life Index. They talk about their own margins, expenses, etc. Do they narrate what counterparties are doing? For example, they mention "our product providers" in the context of ISP sales, but they don't describe those providers' own ramps or expansions. They mention "IPO reinsurers" but that's about their own reinsurance arrangements. They mention "YRT reinsurance rate reductions" but that's about their own negotiations. They mention "clients" but not specific counterparties' trajectories. The key is: does management's forward account consist of reporting on the growth of specific customers, partners, etc., that they already supply? They talk about their sales force growth, but that's their own distribution. They talk about recruiting, but that's their own sales force. They talk about the DOL rule and how they are preparing, but that's their own compliance. They do mention "we have kept our top ISP licensed representatives informed" and "working with them" but that's about their own reps. They mention "we are in discussion with product providers" but that's about their own product lineup. They mention "we expect to incur costs" for DOL implementation. There is no narration of a specific counterparty's own build-out, like a large customer expanding their operations that will drive Primerica's volume. The company is a distributor of insurance and investment products.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.